We are live on
!
Find out more
APM
Avidity Partners Management Portfolio holdings
AUM
$936M
1-Year Est. Return
195%
This Fund
S&P 500
This Quarter
Est. Return
+8.62%
1 Year Est. Return
+195%
3 Year Est. Return
+460.87%
5 Year Est. Return
+815.5%
10 Year Est. Return
–
AUM
$4.71B
AUM Growth
+$793M
(+20%)
Cap. Flow
+$657M
Cap. Flow
% of AUM
13.94%
Top 10 Holdings %
Top 10 Hldgs %
37.6%
Holding
119
New
15
Increased
43
Reduced
17
Closed
21
Top Buys
| 1 |
Elevance Health
ELV
|
+$135M |
| 2 |
AstraZeneca
AZN
|
+$85.6M |
| 3 |
Baxter International
BAX
|
+$72.7M |
| 4 |
Avantor
AVTR
|
+$60.9M |
| 5 |
UnitedHealth
UNH
|
+$55.7M |
Top Sells
| 1 |
Vertex Pharmaceuticals
VRTX
|
+$126M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
+$92.2M |
| 3 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$39.7M |
| 4 |
EXAS
Exact Sciences
EXAS
|
+$35.2M |
| 5 |
CMPS
Compass Pathways
CMPS
|
+$34.7M |
Sector Composition
| 1 | Healthcare | 98.19% |
| 2 | Financials | 0.5% |
| 3 | Technology | 0.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
AbbVie
ABBV
$431B
| $269M | 5.7% |
1,985,000
+371,800
| +23% | +$43.9M |
|
2
Zentalis Pharmaceuticals
ZNTL
$340M
| $228M | 4.84% |
2,715,000
+221,200
| +9% | +$17.1M |
|
3
Arvinas
ARVN
$534M
| $208M | 4.4% |
2,527,973
+293,273
| +13% | +$23.9M |
|
|
4
Avantor
AVTR
$7.65B
| $202M | 4.28% |
4,792,000
+1,544,300
| +48% | +$60.9M |
|
|
5
AstraZeneca
AZN
$261B
| $167M | 3.54% |
1,433,600
+727,600
| +103% | +$85.6M |
|
|
BHVN
6
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $157M | 3.33% |
1,140,000
+205,800
| +22% | +$26.2M |
|
|
7
Baxter International
BAX
$11.4B
| $152M | 3.21% |
1,765,000
+903,000
| +105% | +$72.7M |
|
|
8
Elevance Health
ELV
$84.8B
| $149M | 3.16% |
+321,000
| New | +$135M |
|
9
Pfizer
PFE
$141B
| $123M | 2.62% |
2,090,000
+1,063,200
| +104% | +$52.7M |
|
|
MRTX
10
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $118M | 2.51% |
806,400
-256,000
| -24% | -$39.7M |
|
|
ISEE
11
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $116M | 2.47% |
6,955,000
+2,855,000
| +70% | +$46.8M |
|
12
United Therapeutics
UTHR
$22.6B
| $116M | 2.45% |
535,000
+184,000
| +52% | +$36.1M |
|
|
ARNA
13
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $113M | 2.4% |
1,215,500
+76,500
| +7% | +$5.04M |
|
|
HZNP
14
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $109M | 2.31% |
1,012,000
+186,000
| +23% | +$20.3M |
|
15
Neurocrine Biosciences
NBIX
$17.3B
| $107M | 2.28% |
1,260,000
+411,100
| +48% | +$37.8M |
|
|
BPMC
16
DELISTED
Blueprint Medicines
BPMC
| $107M | 2.26% |
995,000
+163,000
| +20% | +$17.1M |
|
|
SGEN
17
DELISTED
Seagen Inc. Common Stock
SGEN
| $106M | 2.25% |
685,000
+148,000
| +28% | +$24.8M |
|
18
Syndax Pharmaceuticals
SNDX
$2.08B
| $106M | 2.24% |
4,823,400
| – | – |
|
19
Eli Lilly
LLY
$1.03T
| $95.2M | 2.02% |
344,800
+14,800
| +4% | +$3.75M |
|
|
CTLT
20
DELISTED
CATALENT, INC.
CTLT
| $89M | 1.89% |
695,000
+297,000
| +75% | +$38.2M |
|
21
Natera
NTRA
$39.7B
| $87.8M | 1.86% |
940,000
+301,300
| +47% | +$31.3M |
|
|
HOLX
22
DELISTED
Hologic
HOLX
| $81.5M | 1.73% |
1,064,000
+118,600
| +13% | +$8.72M |
|
23
Iovance Biotherapeutics
IOVA
$2.12B
| $72.2M | 1.53% |
3,780,000
+2,317,800
| +159% | +$51M |
|
24
Sotera Health
SHC
$5.18B
| $69.7M | 1.48% |
2,960,000
+582,000
| +24% | +$13.9M |
|
25
Nuvation Bio
NUVB
$2.05B
| $62.8M | 1.33% |
7,382,488
+119,000
| +2% | +$1.09M |
|
Similar funds
NM
LM
IF
PWAM
CM
LJAC
PO
SH